9 stocks have risen 100% this year and could double again
Nine health-care stocks have more than doubled in price this year, but still have more than 100% upside potential, according to analysts. CNBC Pro screened more than 85,000 firms worldwide for stocks that have risen by 100% so far in 2024. They are all covered by at least five or more analysts, and a have a median price target pointing to more than 100% upside potential over the next 12 months. The Nasdaq-listed stocks are Jasper Therapeutics , Corbus Pharmaceuticals , Rezolute , Trevi Therapeutics , Delcath Systems , Benitec Biopharma , Arcutis Biotherapeutics , Praxis Precision Medicines and Humacyte . Stocks in the biotechnology sector are typically classed by analysts as carrying higher risk for investors than other sectors. Jasper Therapeutics Jasper Therapeutics is a clinical-stage b...










